You are here

Responses

Article menu
Download PDFPDF
Original articles
Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder
Compose a Response to This Article
Compose Response

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on: 9 January 2022
    True status of supplement not made clear to reader
    • Charlotte M Wright, Senior Lecturer in community Child Health
    • Other Contributors:
      • Tony Waterston, Tim Cole and Carol Dezateux

    Dear Editor,

    As current or previous members of the ADC editorial board, we wish to register our disquiet about your recent supplement on ADHD.

    Firstly, we are concerned at the principle of publishing something of this kind at all. One of ADC’s great strengths has been the fact that it has not, until now, rented out editorial space to those prepared to pay. Such commercially funded supplements, even if...

    Show More
    Conflict of Interest:
    None declared.
  • Published on: 9 January 2022
    What about the cost?

    Dear Editor,

    I'm unable to find any consideration of the cost of atomoxetine in the article. This is unfortunate as the article is positive towards this new drug , but ignores it's significantly increased cost when compared to methylphenidate.

    Locally we feel this should not be a first line drug due to it's cost , unless there are clear contraindications to methylphenidate.

    Conflict of Interest:
    None declared.